In-body studies have shown that RBT-9 has anti-SARS-CoV-2 activity.

Biotechnology company Reibus Therapeutics announced today that its research therapy RBT-9 has been shown to have in vitro anti-SARS-CoV-2 (the virus that causes COVID-19).
RBT-9 showed extensive antiviral activity against several envelope viruses, as well as protective effects on important organs, including the lungs, heart, kidneys and liver.
the study, conducted through a suite of preclinical services provided by the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), has shown that RBT-9 inhibits the activity of SARS-CoV-2 viruses, especially RBT-9, which is significantly effective in inhibiting virus replication.
S. Stacey Ruiz, Vice President of Drug Development and Medical Affairs at rebecus Therapeutics, said, "We are pleased to have conducted two early independent studies that have shown that RBT-9 has significant antiviral activity against COVID-19.
inhibition of viral replication supports the potential of RBT-9 in the treatment of COVID-19 patients, for which RBT-9 was FDA fast-track certified in May and is currently being evaluated in Phase II clinical trials."
Renibus is currently advancing RBT-9 into Phase II clinical trials for patients with COVID-19 in non-severe adults at risk of disease progression.
more information about this study, please visit ClintonTrials.gov: NCT04364763.
.